Skip to main content
SpringerLink
Log in

The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To study the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide.

Methods

Eighteen healthy male subjects were divided into three groups according to their genotypes: group I, CYP2C9*1/*1 and CYP2C19 extensive metabolizers (EMs); group II, CYP2C9*1/*1 and CYP2C19 poor metabolizers (PMs); and group III, CYP2C9*1/*3 and CYP2C19 EMs. After a single dose of a 5-mg glipizide tablet, plasma concentrations of glipizide for a 36-h period were determined. Meanwhile, plasma glucose levels and plasma insulin levels were determined from 0 to 4 h after dosing.

Results

The area under the plasma concentration-time curve (\( AU{C_{0 - \infty }} \)) was 2.0-fold higher and the oral clearance was 51.1% lower in group III than in group I. The change in fasting insulin level within 1 h (ΔAUECinsulin0–1h) in group III was 3.8-fold higher than that in group I. The glipizide parameters in group II exhibited similar tendencies to those in group III.

Conclusions

These results suggest that CYP2C9 polymorphism significantly influences the pharmacokinetics and pharmacodynamics of glipizide, which needs to be considered in clinical practice. CYP2C19 polymorphism exhibits a tendency to influence the effects of glipizide, to a certain extent similarly to CYP2C9 polymorphism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Fuccella LM, Tamassia V, Valzelli G (1973) Metabolism and kinetics of the hypoglycemic agent glipizide in man — comparison with glibenclamide. J Clin Pharmacol New Drug 13:68–75

    CAS  Google Scholar 

  2. Balant L, Fabre J, Zahnd GR (1975) Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 8:63–69

    Article  CAS  PubMed  Google Scholar 

  3. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9:71–80

    Article  CAS  PubMed  Google Scholar 

  4. Bae JW, Kim NT, Choi CI, Kim MJ, Jang CG, Lee SY (2007) Effects of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects. FASEB J 21:lb362

    Google Scholar 

  5. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–958

    Article  CAS  PubMed  Google Scholar 

  6. Wang SL, Huang J, Lai MD, Tsai JJ (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37–42

    Article  CAS  PubMed  Google Scholar 

  7. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422

    PubMed  Google Scholar 

  8. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598

    Google Scholar 

  9. Zhao XH, Song B, Zhong DF, Zhang SQ, Chen XY (2007) Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry. Acta Pharm Sin 42:1087–1091

    CAS  Google Scholar 

  10. Park JY, Kim KA, Park PW, Park CW, Shin JG (2003) Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 74:334–340

    Article  CAS  PubMed  Google Scholar 

  11. Xie HG, Prasad HC, Kim RB, Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257–1270

    Article  CAS  PubMed  Google Scholar 

  12. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263

    Article  CAS  PubMed  Google Scholar 

  13. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113

    Article  CAS  PubMed  Google Scholar 

  14. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L et al (2009) The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 65:281–285

    Article  CAS  PubMed  Google Scholar 

  15. Cefalu WT (2007) Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. Clin Pharmacol Ther 81:636–649

    Article  CAS  PubMed  Google Scholar 

  16. Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. Eur J Clin Pharmacol 65:365–375

    Article  CAS  PubMed  Google Scholar 

  17. Becquemont L (2008) Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol 64:953–960

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Natural Science Foundation of China grant 30772621.

Author information

Authors and Affiliations

  1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China

    Bo Tan, Yi-Fan Zhang, Xiao-Yan Chen, Xiao-Hua Zhao & Da-Fang Zhong

  2. Departmant of Clinical Pharmacology, The Second Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang, 110034, China

    Guo-Xin Li

  3. 646 Song-Tao Road, Shanghai, 201203, China

    Da-Fang Zhong

Authors
  1. Bo Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi-Fan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Yan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-Hua Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guo-Xin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Da-Fang Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Da-Fang Zhong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, B., Zhang, YF., Chen, XY. et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol 66, 145–151 (2010). https://doi.org/10.1007/s00228-009-0736-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0736-2

Keywords

Search

Navigation